Logo

Kura Oncology Reports the US FDA's Clinical Hold on the P-Ib Study of KO-539 for the Treatment of Acute Myeloid Leukemia

Share this

Kura Oncology Reports the US FDA's Clinical Hold on the P-Ib Study of KO-539 for the Treatment of Acute Myeloid Leukemia

Shots:

  • The US FDA has placed a partial clinical hold on the P-Ib KOMET-001 study to evaluate Kura Oncology’s KO-539 in patients with r/r AML while patients who enrolled in this study will continue to receive KO-539 & no additional patients will enroll until the partial clinical hold is resolved
  • The FDA’s decision is based on Kura’s recent report of a Grade 5 serious AEs (patient death) associated with differentiation syndrome
  • The company is working closely with the US FDA and the site investigators to resolve the partial clinical hold shortly

Click here to­ read full press release

Ref: Kura Oncology | Image: Kura Oncology


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions